IE 11 is not supported. For an optimal experience visit our site on another browser.

FDA Advisory Committee Member discusses future of Johnson & Johnson vaccine


Federal agencies are expected to decide whether the Johnson & Johnson covid-19 vaccine can resume this week. Member of the FDA Vaccine Advisory Committee Dr. Paul Offit weighs in on the vaccine's fate and explains its advantages, but cautions it now has a "scarlet letter" on it.